Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
Respiratory Research volume 22, Article number: 299 (2021)
Correction to: Respir Res (2020) 21:134 https://doi.org/10.1186/s12931-020-01387-z
The original version of the article unfortunately contained a mistake in the disclosure statement.
It has been corrected in this correction.
It should read as,
The disclosure statement was incomplete, the correct statement is “MeiLan K Han received writing and research support from GlaxoSmithKline for this work. Outside this work, she also reports personal fees from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Merck and Mylan. She also reports research support from Novartis and Sunovion.”
Singh D, Criner GJ, Naya I, Jones PW, Tombs L, Lipson DA, Han MK. Measuring disease activity in COPD: is clinically important deterioration the answer? Respir Res. 2020;21:134.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Singh, D., Criner, G.J., Naya, I. et al. Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?. Respir Res 22, 299 (2021). https://doi.org/10.1186/s12931-021-01894-7